More Post from the Author
- Multilingual Conversational Speech Language Model (MLC-SLM) workshop at Interspeech 2025
- Now Live in the UK: Worldwide Club Offers for Travel Enthusiasts
- arrivato il nuovo Bybit Web3: alimenta le emozioni on-chain con 200.000 dollari in palio
- Vortex Companies Promotes Ram Vela to Chief Strategy Officer to Lead Corporate Growth and Global Transformation
- UnionPay International startet eine exklusive Werbeaktion mit der InterContinental Hotels Group fr Besucher aus aller Welt in China
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Multilingual Conversational Speech Language Model (MLC-SLM) workshop at Interspeech 2025
- Now Live in the UK: Worldwide Club Offers for Travel Enthusiasts
- arrivato il nuovo Bybit Web3: alimenta le emozioni on-chain con 200.000 dollari in palio
- Vortex Companies Promotes Ram Vela to Chief Strategy Officer to Lead Corporate Growth and Global Transformation
- UnionPay International startet eine exklusive Werbeaktion mit der InterContinental Hotels Group fr Besucher aus aller Welt in China